LBA
SPRO icon

Letko, Brosseau & Associates’s Spero Therapeutics SPRO Stock Holding History

Letko, Brosseau & Associates’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-73,659
Closed -$147K – 101
2022
Q3 		$147K Hold
73,659
– – ﹤0.01% 95
2022
Q2 		$55K Hold
73,659
– – ﹤0.01% 99
2022
Q1 		$641K Hold
73,659
– – 0.01% 88
2021
Q4 		$1.18M Hold
73,659
– – 0.02% 87
2021
Q3 		$1.36M Hold
73,659
– – 0.02% 88
2021
Q2 		$1.03M Hold
73,659
– – 0.01% 90
2021
Q1 		$1.08M Buy
73,659
+5,559
+8% +$97.8K 0.01% 87
2020
Q4 		$1.32M Buy
+68,100
New +$1.06M 0.02% 87

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Letko, Brosseau & Associates's SPRO Position: Q4 2022 in Review

Letko, Brosseau & Associates sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 73,659 shares — an estimated $147K sold.

Letko, Brosseau & Associates first reported a position in SPRO in Q4 2020 and held it in 8 quarters. The position peaked at $1.36M in Q3 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • Letko, Brosseau & Associates reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 73,659 Spero Therapeutics shares in Q4 2022, an estimated $147K.
  • Letko, Brosseau & Associates first reported a position in Spero Therapeutics in Q4 2020 and held it in 8 quarters.
  • Letko, Brosseau & Associates's Spero Therapeutics position peaked at $1.36M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2022, filed 10 Feb 2023.